The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf179 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Akhilesh Kumar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States. Hauptthemen laut MEDLINE: Killer Cells, Natural, Repressor Proteins, Tumor Suppressor Proteins, Cytotoxicity, Immunologic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Bcl11b is a zinc-finger transcription factor that is required for the differentiation of αβ T cells. A role for BCL11B in the regulation of human natural killer (NK) cell maturation has been inferred from patients with heterozygous mutations in BCL11B. However, mechanistic and functional studies are lacking due to the low efficiency of current transduction and transfection methods. Here, we developed a synthetic BCL11B mRNA with enhanced stability that could be transfected into primary NK cells at high frequencies. Introduction of BCL11B mRNA slowed NK cell proliferation while simultaneously driving maturation and acquisition of cytotoxic granule components. For in vitro and in vivo functional testing, we generated induced pluripotent stem cell (iPSC)-derived NK (iNK) cells with inducible BCL11B expression. These iNK cells mediated faster solid tumor cell killing and significantly better tumor control in vivo. Together, our findings support the notion that BCL11B is a key transcription factor in human NK cells and demonstrate that increased BCL11B expression can enhance NK cell immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States.
- Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
- Centre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
ORCID-Profile: Anna J Weis
Förderung
- NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
- Cichocki and National Cancer Institute, National Institutes of Health Grants
- National Heart, Lung, and Blood Institute
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Kumar, A., Zhang, B., Baldys, A., Fischer, C., Lenvik, A., Felices, M., Davis, Z. B., Bendzick, L., Weis, A. J., Bryceson, Y. T., Miller, J. S., & Cichocki, F. (2025). The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf179
Vancouver
Kumar A, Zhang B, Baldys A, Fischer C, Lenvik A, Felices M, et al. The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf179
BibTeX
@article{Kumar2025,
author = {Kumar, Akhilesh and Zhang, Bin and Baldys, Andrew and Fischer, Colin and Lenvik, Alexander and Felices, Martin and Davis, Zachary B and Bendzick, Laura and Weis, Anna J and Bryceson, Yenan T and Miller, Jeffrey S and Cichocki, Frank},
title = {The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf179}
}
EUVIMED